You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePaliperidone
Accession NumberDB01267
TypeSmall Molecule
GroupsApproved
DescriptionPaliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.
Structure
Thumb
Synonyms
9-Hydroxyrisperidone
Invega
Paliperidone
Ro-76477
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Inc2007-10-02Not applicableCanada
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mg/1OralJanssen Pharmaceuticals, Inc.2006-12-19Not applicableUs
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mg/1OralRebel Distributors Corp2006-12-19Not applicableUs
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mg/1OralJanssen Pharmaceuticals, Inc.2009-09-10Not applicableUs
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mg/1OralREMEDYREPACK INC.2013-03-272016-04-05Us
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen IncNot applicableNot applicableCanada
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mg/1OralJanssen Pharmaceuticals, Inc.2006-12-19Not applicableUs
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Inc2007-10-02Not applicableCanada
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mg/1OralTYA Pharmaceuticals2006-12-19Not applicableUs
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mg/1OralJanssen Pharmaceuticals, Inc.2006-12-19Not applicableUs
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Inc2007-10-02Not applicableCanada
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mg/1OralAvera Mc Kennan Hospital2015-05-29Not applicableUs
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
Invega SustennaSuspension, extended release150 mgIntramuscularJanssen Inc2010-07-21Not applicableCanada
Invega SustennaInjection117 mg/.75mLIntramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega SustennaSuspension, extended release50 mgIntramuscularJanssen Inc2010-07-21Not applicableCanada
Invega SustennaInjection156 mg/mLIntramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega SustennaSuspension, extended release75 mgIntramuscularJanssen Inc2010-07-21Not applicableCanada
Invega SustennaInjection39 mg/.25mLIntramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega SustennaInjection234 mg/1.5mLIntramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega SustennaSuspension, extended release25 mgIntramuscularJanssen IncNot applicableNot applicableCanada
Invega SustennaSuspension, extended release100 mgIntramuscularJanssen Inc2010-07-21Not applicableCanada
Invega SustennaInjection78 mg/.5mLIntramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega TrinzaInjection, suspension, extended release410 mg/1.315mLIntramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega TrinzaSuspension, extended release350 mgIntramuscularJanssen Inc2016-07-25Not applicableCanada
Invega TrinzaInjection, suspension, extended release546 mg/1.75mLIntramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega TrinzaSuspension, extended release525 mgIntramuscularJanssen Inc2016-07-25Not applicableCanada
Invega TrinzaSuspension, extended release175 mgIntramuscularJanssen Inc2016-07-25Not applicableCanada
Invega TrinzaInjection, suspension, extended release819 mg/2.625mLIntramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega TrinzaSuspension, extended release263 mgIntramuscularJanssen Inc2016-07-25Not applicableCanada
Invega TrinzaInjection, suspension, extended release273 mg/.875mLIntramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Mylan-paliperidoneTablet, extended release6 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-paliperidoneTablet, extended release3 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PaliperidoneTablet, extended release9 mg/1OralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
PaliperidoneTablet, extended release3 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
PaliperidoneTablet, extended release1.5 mg/1OralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
PaliperidoneTablet, extended release3 mg/1OralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
PaliperidoneTablet, extended release1.5 mg/1OralAvera Mc Kennan Hospital2015-09-29Not applicableUs
PaliperidoneTablet, extended release6 mg/1OralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
XeplionInjection, suspension, extended release150 mgIntramuscularJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionInjection, suspension, extended release50 mgIntramuscularJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionInjection, suspension, extended release75 mgIntramuscularJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionInjection, suspension, extended release100 mgIntramuscularJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionInjection, suspension, extended release25 mgIntramuscularJanssen Cilag International N.V.2011-03-04Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaliperidoneTablet, film coated, extended release9 mg/1OralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release1.5 mg/1OralActavis Pharma, Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release1.5 mg/1OralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release3 mg/1OralMylan Institutional Inc.2016-09-20Not applicableUs
PaliperidoneTablet, film coated, extended release3 mg/1OralActavis Pharma, Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release3 mg/1OralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralMylan Institutional Inc.2016-09-15Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralActavis Pharma, Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralCarilion Materials Management2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release9 mg/1OralActavis Pharma, Inc.2015-09-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paliperidone palmitate
ThumbNot applicableDBSALT001464
Categories
UNII838F01T721
CAS number144598-75-4
WeightAverage: 426.4839
Monoisotopic: 426.206718955
Chemical FormulaC23H27FN4O3
InChI KeyPMXMIIMHBWHSKN-UHFFFAOYSA-N
InChI
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
IUPAC Name
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
SMILES
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Pharmacology
IndicationFor the treatment of schizophrenia.
Structured Indications
PharmacodynamicsPaliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways.
Mechanism of actionPaliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
Histamine H1 receptorProteinunknown
agonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
D(4) dopamine receptorProteinyes
antagonist
HumanP21917 details
5-hydroxytryptamine receptor 1DProteinunknown
antagonist
HumanP28221 details
D(3) dopamine receptorProteinyes
antagonist
HumanP35462 details
5-hydroxytryptamine receptor 2CProteinyes
antagonist
HumanP28335 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
agonist
HumanP18825 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
Cytochrome P450 3A4ProteinunknownNot AvailableHumanP08684 details
Cytochrome P450 2D6ProteinunknownNot AvailableHumanP10635 details
Cytochrome P450 3A5ProteinunknownNot AvailableHumanP20815 details
Related Articles
AbsorptionThe absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
Volume of distribution
  • 487 L
Protein bindingThe plasma protein binding of racemic paliperidone is 74%.
Metabolism

Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone. Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Paliperidone does not undergo extensive metabolism and a significant portion of its metabolism occurs in the kidneys.

Route of eliminationOne week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered.
Half lifeThe terminal elimination half-life of paliperidone is approximately 23 hours.
ClearanceNot Available
ToxicityThe possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Paliperidone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetaminePaliperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePaliperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with 7-Nitroindazole.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Paliperidone.Approved, Investigational
AcebutololPaliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Paliperidone.Withdrawn
adipiplonThe risk or severity of adverse effects can be increased when Paliperidone is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Agomelatine.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Paliperidone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Paliperidone.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.Approved, Illicit, Investigational
AlprenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Paliperidone.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Paliperidone.Illicit, Withdrawn
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Paliperidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Paliperidone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amperozide.Experimental
AmphetaminePaliperidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideAnagrelide may increase the QTc-prolonging activities of Paliperidone.Approved
Aop200704Paliperidone may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ArotinololPaliperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ArtemetherPaliperidone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Articaine.Approved
AsenapinePaliperidone may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AtenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Azaperone.Vet Approved
AzelastinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Paliperidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Paliperidone.Approved
BefunololPaliperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Paliperidone.Approved
BenzphetaminePaliperidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benzyl alcohol.Approved
BetaxololPaliperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Paliperidone.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brotizolam.Approved, Withdrawn
BucindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Paliperidone.Withdrawn
BufuralolPaliperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paliperidone.Approved, Investigational
BupranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Paliperidone.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paliperidone.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.Approved
CarbamazepineThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carisoprodol.Approved
CarteololPaliperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolPaliperidone may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Paliperidone.Experimental
CeliprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibCeritinib may increase the QTc-prolonging activities of Paliperidone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Paliperidone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paliperidone.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorphenamine.Approved
ChlorphenterminePaliperidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paliperidone.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorzoxazone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Paliperidone.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paliperidone.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Paliperidone.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Paliperidone.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paliperidone.Approved, Illicit
ClozapineClozapine may increase the QTc-prolonging activities of Paliperidone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Paliperidone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.Approved, Illicit
CrizotinibCrizotinib may increase the QTc-prolonging activities of Paliperidone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Paliperidone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyproheptadine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Paliperidone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paliperidone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Paliperidone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Paliperidone.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Paliperidone is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Paliperidone.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Paliperidone.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Paliperidone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paliperidone.Approved, Vet Approved
DextroamphetaminePaliperidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Paliperidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Paliperidone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone.Approved, Illicit, Vet Approved
DiethylpropionPaliperidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paliperidone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Paliperidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.Approved, Illicit
DisopyramideDisopyramide may increase the QTc-prolonging activities of Paliperidone.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Paliperidone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Paliperidone.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Paliperidone.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Paliperidone.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Paliperidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Illicit
DronedaronePaliperidone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone.Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Paliperidone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paliperidone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Paliperidone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Paliperidone is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.Approved, Investigational
EliglustatPaliperidone may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Paliperidone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paliperidone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Paliperidone.Investigational
EsmololPaliperidone may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paliperidone.Approved
EthanolPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paliperidone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Paliperidone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etorphine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Paliperidone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Paliperidone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Paliperidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Paliperidone.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Paliperidone.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flibanserin.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Paliperidone.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Paliperidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Paliperidone.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Paliperidone.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Paliperidone is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Paliperidone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Paliperidone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Paliperidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Paliperidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Paliperidone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Paliperidone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Paliperidone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Paliperidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Paliperidone.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Paliperidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Paliperidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Paliperidone.Approved
HydrocodonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.Approved, Illicit
Hydroxyamphetamine hydrobromidePaliperidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Paliperidone.Approved
IloperidonePaliperidone may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may decrease the antihypertensive activities of Paliperidone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Paliperidone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Paliperidone.Approved
IndenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Paliperidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Paliperidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Paliperidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Paliperidone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Paliperidone.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Paliperidone.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Paliperidone.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Paliperidone.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paliperidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketobemidone.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
LabetalolPaliperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Paliperidone.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paliperidone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Paliperidone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Paliperidone.Approved
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Paliperidone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Paliperidone.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Paliperidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Paliperidone.Approved
LisdexamfetaminePaliperidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Paliperidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lofentanil.Illicit
LopinavirPaliperidone may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Paliperidone.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Paliperidone is combined with Lu AA21004.Investigational
LumefantrinePaliperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Paliperidone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Paliperidone.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Paliperidone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Melperone.Approved
MephedronePaliperidone may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePaliperidone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paliperidone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.Approved, Illicit
MequitazinePaliperidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paliperidone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Paliperidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetaminePaliperidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paliperidone.Approved
MethotrimeprazinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paliperidone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paliperidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.Approved, Investigational
MetoprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Paliperidone.Approved
MetyrosinePaliperidone may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Paliperidone.Approved
MilnacipranMilnacipran may decrease the antihypertensive activities of Paliperidone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Paliperidone.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Paliperidone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Paliperidone.Approved, Investigational
MMDAPaliperidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Paliperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Paliperidone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Investigational
NadololPaliperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Paliperidone.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Paliperidone.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Paliperidone.Approved
NilotinibPaliperidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Paliperidone.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Paliperidone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olopatadine.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Paliperidone.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Paliperidone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Opium.Approved, Illicit
OrphenadrinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Oxetacaine.Investigational
OxprenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paliperidone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ParaldehydePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Paliperidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Paliperidone.Approved
PenbutololPaliperidone may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Paliperidone.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paliperidone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Paliperidone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Paliperidone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Paliperidone.Approved, Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenoxyethanol.Approved
PhenterminePaliperidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Paliperidone.Approved
PindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Paliperidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Vet Approved
PractololPaliperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexolePaliperidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Paliperidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paliperidone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Paliperidone.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Paliperidone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Paliperidone.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Paliperidone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Paliperidone.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Paliperidone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paliperidone.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Propoxycaine.Approved
PropranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Paliperidone.Approved
PSD502The risk or severity of adverse effects can be increased when Paliperidone is combined with PSD502.Investigational
PseudoephedrinePaliperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Quazepam.Approved, Illicit
QuetiapineQuetiapine may increase the QTc-prolonging activities of Paliperidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Paliperidone.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Paliperidone.Approved
QuinineQuinine may increase the QTc-prolonging activities of Paliperidone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ramelteon.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paliperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paliperidone.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Paliperidone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ritanserin.Investigational
RitobegronPaliperidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Romifidine.Vet Approved
RopinirolePaliperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Paliperidone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone.Approved, Investigational
RotigotinePaliperidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Paliperidone is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Paliperidone is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Paliperidone.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Paliperidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Paliperidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Paliperidone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Paliperidone.Approved
St. John's WortThe serum concentration of Paliperidone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Paliperidone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Paliperidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
SuvorexantPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Paliperidone.Approved
TandospironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Paliperidone.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Paliperidone.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Paliperidone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Paliperidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrodotoxin.Investigational
ThalidomidePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paliperidone.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Paliperidone.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Paliperidone.Approved, Vet Approved
ThioridazineThioridazine may increase the QTc-prolonging activities of Paliperidone.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Paliperidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Paliperidone.Approved
TiaprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiletamine.Vet Approved
TimololPaliperidone may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Paliperidone.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Topiramate.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paliperidone.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paliperidone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paliperidone.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Paliperidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Paliperidone.Withdrawn
Uc1010The risk or severity of adverse effects can be increased when Paliperidone is combined with Uc1010.Investigational
Valproic AcidThe serum concentration of Paliperidone can be increased when it is combined with Valproic Acid.Approved, Investigational
VandetanibPaliperidone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Paliperidone.Approved
VemurafenibPaliperidone may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Paliperidone.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Paliperidone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Paliperidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Paliperidone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Paliperidone.Approved, Investigational
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Paliperidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone.Approved, Investigational
ZolpidemPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paliperidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zotepine.Approved
ZuclopenthixolPaliperidone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
References
Synthesis Reference

Santiago Ini, Naama Chasid, Kobi Chen, Osnat Porter-Kleks, “Pure paliperidone and processes for preparing thereof.” U.S. Patent US20080171876, issued July 17, 2008.

US20080171876
General References
  1. Jones MP, Nicholl D, Trakas K: Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99. [PubMed:20497747 ]
  2. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
External Links
ATC CodesN05AX13
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7928
Caco-2 permeable-0.5496
P-glycoprotein substrateSubstrate0.7449
P-glycoprotein inhibitor IInhibitor0.7011
P-glycoprotein inhibitor IIInhibitor0.8229
Renal organic cation transporterNon-inhibitor0.6231
CYP450 2C9 substrateNon-substrate0.7721
CYP450 2D6 substrateSubstrate0.5131
CYP450 3A4 substrateSubstrate0.7154
CYP450 1A2 substrateNon-inhibitor0.7379
CYP450 2C9 inhibitorNon-inhibitor0.7395
CYP450 2D6 inhibitorNon-inhibitor0.5326
CYP450 2C19 inhibitorNon-inhibitor0.7815
CYP450 3A4 inhibitorNon-inhibitor0.6468
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7558
Ames testNon AMES toxic0.518
CarcinogenicityNon-carcinogens0.7995
BiodegradationNot ready biodegradable0.9908
Rat acute toxicity3.7859 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Inhibitor0.7061
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral1.5 mg
Tablet, extended releaseOral12 mg
Tablet, extended releaseOral3 mg
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral6 mg
Tablet, extended releaseOral6 mg/1
Tablet, extended releaseOral9 mg
InjectionIntramuscular117 mg/.75mL
InjectionIntramuscular156 mg/mL
InjectionIntramuscular234 mg/1.5mL
InjectionIntramuscular39 mg/.25mL
InjectionIntramuscular78 mg/.5mL
Suspension, extended releaseIntramuscular100 mg
Suspension, extended releaseIntramuscular150 mg
Suspension, extended releaseIntramuscular25 mg
Suspension, extended releaseIntramuscular50 mg
Suspension, extended releaseIntramuscular75 mg
Injection, suspension, extended releaseIntramuscular273 mg/.875mL
Injection, suspension, extended releaseIntramuscular410 mg/1.315mL
Injection, suspension, extended releaseIntramuscular546 mg/1.75mL
Injection, suspension, extended releaseIntramuscular819 mg/2.625mL
Suspension, extended releaseIntramuscular175 mg
Suspension, extended releaseIntramuscular263 mg
Suspension, extended releaseIntramuscular350 mg
Suspension, extended releaseIntramuscular525 mg
Tablet, extended releaseOral1.5 mg/1
Tablet, extended releaseOral9 mg/1
Tablet, film coated, extended releaseOral1.5 mg/1
Tablet, film coated, extended releaseOral3 mg/1
Tablet, film coated, extended releaseOral6 mg/1
Tablet, film coated, extended releaseOral9 mg/1
Injection, suspension, extended releaseIntramuscular100 mg
Injection, suspension, extended releaseIntramuscular150 mg
Injection, suspension, extended releaseIntramuscular25 mg
Injection, suspension, extended releaseIntramuscular50 mg
Injection, suspension, extended releaseIntramuscular75 mg
Prices
Unit descriptionCostUnit
Invega sustenna 39 mg pref syringe296.45USD syringe
Invega er 6 mg tablet28.62USD tablet
Invega er 9 mg tablet23.59USD tablet
Invega er 3 mg tablet23.09USD tablet
Invega er 1.5 mg tablet15.72USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2000786 No1999-01-262009-10-16Canada
CA2494234 No2009-10-272023-07-28Canada
US5254556 No1993-10-272010-10-27Us
US6077843 Yes1997-11-122017-11-12Us
US6555544 Yes1999-05-102019-05-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insoluble in waterNot Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.297 mg/mLALOGPS
logP2.3ALOGPS
logP1.76ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area82.17 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.04 m3·mol-1ChemAxon
Polarizability45.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridopyrimidines
Sub ClassNot Available
Direct ParentPyridopyrimidines
Alternative Parents
Substituents
  • Pyridopyrimidine
  • Benzisoxazole
  • Aralkylamine
  • Pyrimidone
  • Fluorobenzene
  • Benzenoid
  • Pyrimidine
  • Pyridine
  • Piperidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Oxazole
  • Isoxazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Lactam
  • Oxacycle
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. He H, Richardson JS: A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995 Mar;10(1):19-30. [PubMed:7542676 ]
  3. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  4. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse. 2002 Oct;46(1):32-7. [PubMed:12211096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  3. Regenthal R, Kunstler U, Hesse S, Sabri O, Preiss R: D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. Int J Clin Pharmacol Ther. 2005 Aug;43(8):370-8. [PubMed:16119512 ]
  4. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401. [PubMed:16513859 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse. 2002 Oct;46(1):32-7. [PubMed:12211096 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  5. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  6. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932 ]
  7. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  8. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  5. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  6. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932 ]
  7. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  8. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gunes A, Spina E, Dahl ML, Scordo MG: ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33. doi: 10.1097/FTD.0b013e3181858ca9. [PubMed:18708991 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Boerth JM, Caley CF, Goethe JW: Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302. [PubMed:15767244 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8. [PubMed:11560868 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 14:09 / Updated on December 07, 2016 03:54